Tirzepatide has the potential to dramatically enhance the load loss market, sa

US pharmaceuticals major Eli Lilly (NYSE: LLY) recently announced top-line results for tirzepatide from its Phase III SURMOUNT-1 clinical trial, which has shaken up the prospects for the pharmacologic weight management market, a sector which is now dominated by Novo Nordisk (Denmark) (NOV:N).

Participants taking the drug tirzepatide lost up to 52 pounds (24 kg) in the 72-week phase III study, with 63% of participants taking tirzepatide 15 mg losing at least…

This article is available to registered users, to continue reading please register for free. A free trial gives you one-week access to exclusive features, interviews, recaps and commentary from the brightest minds in pharma and biotechnology. If you are already a registered user, please log in. If your trial has expired, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life science reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

become a subscriber

• Unrestricted access to industry-leading pharma and biotech news, commentary and analysis.
• Updates on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulation, patents and law, executive appointments, business strategy and financial results.
• Daily summary of important events in pharma and biotech.
• Monthly in-depth briefings on board meetings and M&A news.
• Choose from an affordable annual package or a flexible monthly subscription.

Comments are closed.